The mRNA revolution didn’t end with COVID-19 – it’s only just beginning. With the MHRA’s latest guidance on personalized mRNA cancer vaccines and the world’s first RNA-based CRISPR therapy changing lives, the technology is stepping confidently into a new era of gene editing, therapeutic development, and vaccine innovation.
Now, the challenge is scaling safely and effectively. From optimizing mRNA, saRNA, and circular RNA design to perfecting delivery systems and ensuring validated clinical safety, biopharma leaders are racing to translate potential into real-world impact.
This eBook explores how the world’s leading experts are driving that progress – revealing the breakthroughs, partnerships, and strategies shaping the next generation of RNA medicines.
Inside, you’ll discover:
- The latest mRNA, saRNA, and circular RNA design and delivery innovations
- How transient gene-editing strategies are redefining the therapeutic landscape
- Insights from investor-led sessions on building fundable mRNA platforms for 2026
- Expert perspectives from Moderna, AstraZeneca, CybernaX Bio, Avocet Bio, and more
Access your free copy to learn how the 5th mRNA-Based Therapeutics Summit Europe is empowering biopharma to unlock the full potential of mRNA for vaccines, gene editing, and advanced therapeutics.
About Hanson Wade Group - 5th mRNA-Based Therapeutics Summit Europe
Boosting mRNA Potential for Therapeutics, Gene-Editing & Vaccine Applications With Scalable Design, Guided Delivery, & Validated Clinical Safety for Patients
With proof-of-concept after the COVID-19 pandemic, the mRNA space stands on firmer ground and is now making headlines that prove its value across new diseases. From MHRA’s latest guidance on mRNA personalized cancer vaccines to the world’s first RNA-based CRISPR therapy for Baby KJ, doors are opening to revolutionary therapeutics and gene editing applications.
The 5th mRNA-Based Therapeutics Summit Europe is the ultimate biopharma platform diving into novel mRNA, siRNA, and circular RNA design to deliver innovations, giving you the latest insights and connections to turn these breakthroughs into action. Enhanced with the brand-new Gene Editing Focus Day to harness mRNA's power through transient editing strategies, and Investor-Led sessions on what makes an mRNA platform fundable in 2026, leave this meeting with tried and tested strategies to de-risk your programs and secure partnerships in today’s competitive landscape.
Join 170+ senior leaders from Moderna, AstraZeneca, CybernaX Bio, Avocet Bio, and others working on R&D, CMC, business development, and regulatory affairs for three days of learning, networking, and collaboration to put you at the forefront of mRNA and gene editing innovation in 2026.
Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.net, which is to educate and inform site visitors interested in medical research, science, medical devices, and treatments.